Zhejiang Jolly Pharmaceutical Co.,LTD
300181.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.19B
Close$
$24.29
84.3% upside
Current Fair Value
84.3% upsideUndervalued by 84.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.19 Billion |
|---|---|
| Enterprise Value | $9.32 Billion |
| Dividend Yield | $0.35 (5.28%) |
| Earnings per Share | $0.92 |
| Beta | 0.12 |
| Outstanding Shares | 695,439,261 |
Return
| Return on Equity | 19.04% |
|---|---|
| Return on Assets | 12.18% |
| Return on Invested Capital | 22.81% |
Valuation & Multiples
| P/E Ratio | 14.4 |
|---|---|
| PEG | -162.84 |
| Price to Sales | 3.3 |
| Price to Book Ratio | 3.3 |
| Enterprise Value to Revenue | 2.91 |
| Enterprise Value to EBIT | 11.53 |
| Enterprise Value to Net Income | 14 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.24 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 28, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$866.34 M
Average shareholder expectationNext Earnings Call
Expected Date
October 28, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$907.75 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Zhejiang Jolly Pharmaceutical Co.,LTD
2,861 employees
CEO: Tao Wang Zhejiang Jolly Pharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the research, manufacturing, and global distribution of traditional Chinese medicinal products. The company's diverse portfolio includes the Wuling capsule, pre...